	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M PR	12M PR	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS	12M IR
Total Revenue	33.74	44.86	50.99	66.68	54.42	61.02	97.69	88.64	122.39	121.02	140.44	144.92	150.94	206.38	237.53
Cost of Operating Revenue	27.93	35.28	40.48	54.18	42.00	44.50	81.03	68.85	93.83	89.37	107.59	112.79	122.11	154.42	182.80
Gross Profit	5.81	9.58	10.51	12.50	12.42	16.52	16.66	19.79	28.55	31.65	32.85	32.13	28.83	51.96	54.73
Gross Margin	17.2	21.4	20.6	18.7	22.8	27.1	17.1	22.3	23.3	26.2	23.4	22.2	19.1	25.2	23.0
Total Operating Expenses	32.69	43.41	49.34	64.21	51.46	58.55	96.44	87.46	118.81	115.89	133.54	134.89	138.97	192.44	223.07
Operating Profit	1.05	1.45	1.65	2.48	2.95	2.48	1.25	1.18	3.58	5.13	6.90	10.03	11.97	13.93	14.45
Operating Margin	3.1	3.2	3.2	3.7	5.4	4.1	1.3	1.3	2.9	4.2	4.9	6.9	7.9	6.8	6.1
Financing Income/(Expense) - Net	-0.41	-0.61	-0.82	-0.85	-1.33	-1.52	-0.98	-1.06	-0.31	1.35	3.10	1.21	1.43	-1.81	-1.93
Profit before Taxes	0.71	0.96	1.10	1.87	1.69	1.87	2.18	2.22	3.69	6.55	10.10	11.33	13.50	18.06	18.97
Income Taxes	0.28	0.33	0.31	0.74	0.06	0.65	0.60	0.58	1.09	1.66	2.86	3.04	3.41	4.94	5.15
Profit after Tax	0.43	0.63	0.79	1.13	1.63	1.22	1.57	1.63	2.59	4.89	7.24	8.29	10.09	13.12	13.82
PAT Margin	1.3	1.4	1.6	1.7	3.0	2.0	1.6	1.8	2.1	4.0	5.2	5.7	6.7	6.4	5.8
EPS - Basic - ex Extraordinary Items	0.05	0.08	0.10	0.14	0.20	0.18	0.19	0.20	0.31	0.59	0.87	1.00	1.22	1.58	1.67
EPS - Diluted - ex Extraordinary Items	0.05	0.08	0.10	0.14	0.20	0.18	0.19	0.20	0.31	0.59	0.87	1.00	1.22	1.58	1.67
EBIT	1.05	1.45	1.65	2.48	2.95	2.48	1.25	1.18	3.58	5.13	6.90	10.03	11.97	13.93	14.45
EBITDA	1.46	2.20	2.90	3.66	4.01	3.48	2.76	2.84	5.23	7.21	9.62	12.91	15.00	17.03	17.50
EBITDA Margin	4.3	4.9	5.7	5.5	7.4	5.7	2.8	3.2	4.3	6.0	6.9	8.9	9.9	8.3	7.4

Balance Sheet

Abridged

Understanding Balance Sheet

Medico Remedies Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	PR	PR	PR	PR	PR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	13.65	23.34	26.23	36.83	38.12	45.69	59.18	56.64	58.54	58.56	64.54	73.76	96.68	128.92
Long-Term Investments	0.58	0.33	1.04	0.51	0.16	0.24	0.15	0.15	0.11	-	0.79	0.76	1.05	0.88
Property Plant & Equipment - Net	4.04	7.54	7.97	7.09	9.61	11.00	13.16	14.83	15.31	16.09	21.83	21.37	21.58	22.95
Total Non-Current Assets	4.67	7.90	9.51	8.72	10.13	13.69	17.13	18.63	17.08	17.63	22.91	22.43	23.12	24.49
Total Assets	18.33	31.24	35.74	45.54	48.25	59.39	76.31	75.27	75.62	76.19	87.45	96.20	119.80	153.40
Total Current Liabilities	12.66	21.98	21.51	26.41	20.95	30.17	45.45	40.48	37.95	37.89	41.52	42.81	56.96	77.64
Long Term Debt	-	-	-	3.70	10.59	2.19	2.37	4.71	4.95	0.90	1.55	0.87	0.37	0.29
Total Non-Current Liabilities	0.61	0.69	0.63	4.39	10.93	2.55	2.63	4.92	5.21	0.98	2.08	1.01	0.37	0.29
Total Liabilities	13.27	22.67	22.13	30.80	31.87	32.72	48.07	45.40	43.16	38.87	43.61	43.82	57.33	77.93
Total Shareholders' Equity	5.06	8.57	13.61	14.74	16.37	26.67	28.24	29.87	32.46	37.32	43.84	52.37	62.47	75.47
Total Equity	5.06	8.57	13.61	14.74	16.37	26.67	28.24	29.87	32.46	37.32	43.84	52.37	62.47	75.47
Total Liabilities & Equity	18.33	31.24	35.74	45.54	48.25	59.39	76.31	75.27	75.62	76.19	87.45	96.20	119.80	153.40

Cash Flow

Abridged

Understanding Cash Flow Statement

Medico Remedies Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	C 2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	C 2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M PR	12M PR	12M PR	12M PR	12M PR	12M AR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	0.55	1.37	1.80	2.50	2.00	2.34	3.05	3.33	4.40	6.84	10.33	11.79	12.24	16.32
Working Capital - Increase/(Decrease)	-1.61	-2.01	-2.35	-9.17	-4.11	-0.15	0.96	0.34	-16.63	-5.74	-0.93	-7.92	-14.33	-15.32
Net CF from Operating Activities	-1.06	-0.64	-0.55	-6.67	-2.11	2.20	4.01	3.67	-12.23	1.10	9.40	3.87	-2.08	1.01
Capital Expenditures - Net	1.77	4.24	1.53	0.30	3.57	0.79	3.68	3.33	16.96	2.86	6.59	2.47	3.18	4.42
Net CF from Investing Activities	-1.68	-3.94	-2.22	0.20	-3.22	-5.05	-4.74	-3.47	-16.96	-2.86	-6.67	-2.77	-3.56	-4.65
Stock - Issuance/(Retirement) - Net	-	0.23	0.34	-	1.60	9.07	-	-	4.15	12.45	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	2.71	2.83	-0.99	5.32	5.44	1.79	0.69	-3.15	15.05	-4.44	-1.68	-1.83	6.56	4.45
Net Cash Flow from Financing Activities	2.71	5.72	3.25	5.30	5.52	2.36	0.69	0.28	19.20	8.01	-2.98	-1.83	6.56	4.45
Free Cash Flow to Equity	-0.12	-2.05	-3.07	-1.65	-0.25	3.19	1.02	-2.80	-14.14	-6.20	1.14	-0.43	1.29	1.03
Free Operating CF net dividend	-2.83	-4.89	-2.67	-6.97	-5.68	1.40	0.33	0.34	-29.19	-1.76	2.81	1.39	-5.27	-3.48
Free Operating CF	-2.83	-4.89	-2.67	-6.97	-5.68	1.40	0.33	0.34	-29.19	-1.76	2.81	1.39	-5.27	-3.48

Business Segment Analysis

FY End:

Mar 25

Medico Remedies Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceutical formulation manufacturing company (100.0%)₹ 3.19 Cr

Revenue / Sales

Pharmaceutical formulation manufacturing company (100.0%)₹ 150.94 Cr

Assets

Pharmaceutical formulation manufacturing company (100.0%)₹ 119.80 Cr

Operating Income

Pharmaceutical formulation manufacturing company (100.0%)₹ 11.97 Cr

Regional Segment Analysis

Medico Remedies Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Medico Remedies Ltd.

Historical Segment Analysis

Track how Medico Remedies Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2025 Mar 31
	2025 Mar 31
Pharmaceutical formulation manufacturing company	3

Frequently Asked Questions

What is the revenue of Medico Remedies Ltd.?

The latest trailing twelve month revenue of Medico Remedies Ltd. is ₹ 237.53 Cr, reflecting a 1-year growth of 49.96% and a 3-year CAGR of 19.62%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Medico Remedies Ltd.?

The latest trailing twelve month net profit (PAT) of Medico Remedies Ltd. is ₹ 13.81 Cr, with a 3-year earnings CAGR of 19.02%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Medico Remedies Ltd.?

The trailing twelve month EBITDA of Medico Remedies Ltd. is approximately ₹ 14.45 Cr (based on an operating margin of 6.08%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Medico Remedies Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Medico Remedies Ltd. is 1.67. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Medico Remedies Ltd.?

The debt-to-equity ratio of Medico Remedies Ltd. stands at 0.25. The interest coverage ratio is 7.48x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Medico Remedies Ltd.?

The estimated book value per share of Medico Remedies Ltd. is 9.04 (derived from a P/B ratio of 4.63 and market price of ₹ 41.84), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Medico Remedies Ltd.?

The trailing twelve month operating cash flow of Medico Remedies Ltd. is ₹ 1.01 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Medico Remedies Ltd. report consolidated or standalone financials?

Medico Remedies Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.